GlassScriptPhysician profile
Rocco A Rossi
NPI 1487966073
$5,983.35
in general payments reported to CMS, 2019-2025
46 companies · $17.35 in 2025
The $17.35 reported for 2025 was less than what a typical Geriatric Medicine (Family Medicine) provider received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,952 · 2020: $966 · 2021: $2,031 · 2023: $17.04 · 2025: $17.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,218.03 | 2019-2021 | |
| Pfizer INC. | $621.18 | 2019-2021 | |
| Lilly USA, LLC | $413.96 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $368.53 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $299.56 | 2019-2021 | |
| Abbvie INC. | $257.13 | 2019-2021 | |
| Amgen INC. | $245.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $231.30 | 2019-2021 | |
| Astellas Pharma US INC | $219.76 | 2019-2021 | |
| Radius Health, INC. | $200.29 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $167.15 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $125.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $116.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $115.87 | 2019 | |
| Amarin Pharma, INC. | $113.77 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocco Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.